This article first appeared on GuruFocus .
-
Total Investment Income:$30 million in Q4 2025.
-
Net Investment Income:$11.6 million in Q4 2025.
-
Funded Loans:$42.9 million in Q4 2025.
-
Net Investment Income Per Share:$0.32 in Q4 2025.
-
Base Dividend Per Share:$0.33 in Q4 2025.
-
Spillover Income Per Share:Approximately $0.65 at year-end 2025.
-
Debt Portfolio Yield:14.2% annualized in Q4 2025.
-
Total Operating Expenses:$18.4 million in Q4 2025.
-
Net Realized Loss on Investments:$377,000 in Q4 2025.
-
Fair Value of Investment Portfolio:$927.4 million at year-end 2025.
-
Net Assets:$484.9 million at year-end 2025.
-
NAV Per Share:$13.42 at year-end 2025.
-
Total Available Liquidity:$395.2 million at year-end 2025.
-
Unfunded Commitments:$145.5 million at year-end 2025.
-
Leverage Ratio:0.9 at year-end 2025.
-
Asset Coverage Ratio:2.11 times at year-end 2025.
Release Date: March 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Runway Growth Finance Corp ( NASDAQ:RWAY ) delivered total investment income of $30 million and net investment income of $11.6 million in the fourth quarter of 2025.
-
The company completed seven investments in new and existing portfolio companies, totaling $42.9 million in funded loans, across high-growth sectors like technology, healthcare, and select consumer sectors.
-
RWAY's pending acquisition of SWK Holdings is expected to diversify its portfolio, particularly enhancing exposure in healthcare and life sciences.
-
The company's pipeline is stronger than the previous year, indicating potential for growth in 2026.
-
RWAY's debt portfolio generated a dollar-weighted average annualized yield of 14.2% for the fourth quarter of 2025, showcasing strong returns.
Negative Points
-
Net investment income decreased from $15.7 million in the third quarter of 2025 to $11.6 million in the fourth quarter.
-
The weighted average portfolio risk rating increased slightly to 2.45 in the fourth quarter, indicating a marginal increase in risk.
-
The total investment portfolio's fair value decreased by 2% from the third quarter of 2025.
-
Prepayment fee income declined sequentially, contributing to the decrease in net investment income.
-
The company experienced a net realized loss on investments of $377,000 in the fourth quarter of 2025.
Q & A Highlights
Q: Can you provide an update on the current pipeline and how it compares to last year, particularly in terms of new versus add-on opportunities and industry focus? A: David Spreng, CEO: The pipeline is stronger than last year, largely due to the impact of BC Partners on our deal flow. We expect to do at least one deal per quarter with them. SWK Holdings also presents opportunities to upsize loans. Our normal deal flow remains strong, and we are seeing interesting opportunities with good returns, especially in software and consumer sectors. However, we remain conservative in our underwriting approach.
Q: What is the expected pro forma leverage after the first quarter actions, and how are you thinking about the appropriate level of leverage for the portfolio? A: Unidentified Company Representative: Post-SWK, leverage will be just under 1.2. We aim to run between 1.2 and 1.3 as our fully levered run rate. We may temporarily run higher if we anticipate prepayments, but generally, we won't exceed 1.35.
Q: Are there any updates on the CDM JV? A: Unidentified Company Representative: We continue to work actively with CDM, and expect the first distribution from the JV in Q2. Building the portfolio has been challenging due to aggregate deal flow, but there is a renewed effort to enhance earnings power.
Q: Can you update us on the changes in the SWK Holdings portfolio since the deal announcement? A: Unidentified Company Representative: There will be 13 loans with a fair value of around $235 million, plus an equity portfolio including stock positions and warrants. The aggregate yield on the total portfolio is about 14%, with the debt-only portfolio yielding about 16%.
Q: Regarding the SWK transaction, how should we think about the accretion level from an NII per share perspective given stock price movements? A: Unidentified Company Representative: The equity amount is set at $75.5 million, and the number of shares will change based on NAV. There will still be meaningful accretion, and the NII contribution may increase as the stock price declines, due to the discount at which we're buying the portfolio.
Q: Will you resume share repurchases post-acquisition? A: Unidentified Company Representative: We plan to discuss this with the board. We couldn't repurchase shares due to the pending acquisition and blackout periods. The earliest we could resume is the second week of May, balancing new deals and immediate accretion from buying at a discount.
Q: What is remaining under your repurchase authorization? A: Unidentified Company Representative: We can't use the current authorization, but we'll revisit the number at our board meeting in late April or early May.
Q: Was there a reason for the delay in mailing out proxy materials for the merger? A: Unidentified Company Representative: The SEC took longer than usual to respond due to a backlog and the complexity of the transaction. Once we received comments, we filed as quickly as possible. There were no underlying business issues causing the delay.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
